Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer’s disease: a systematic review and network meta-analysis of... by Wenting Cai, Wenting Cai, Hui Zhang, Hui Zhang, Yan Wu, Yan Wu, Yao Yao, Jinping Zhang

“…Tau protein aggregation, a key pathological feature of AD, is closely associated with neurodegeneration and cognitive decline. Targeting tau protein has emerged as a promising therapeutic strategy. …”
Get full text

Middle-age cerebral small vessel disease and cognitive function in later life: a population-based prospective cohort studyResearch in context by Ali Tanweer Siddiquee, Yoon Ho Hwang, Soriul Kim, Sung Jin Shin, Ji Soo Lee, June Christoph Kang, Min-Hee Lee, Hyeon Jin Kim, Seung Ku Lee, Chol Shin

“…We investigated the relationship between cSVD and cognitive decline over time in middle-aged through elderly population. …”
Get full text

Association of body composition with neuroimaging biomarkers and cognitive function; a population-based study of 70-year-oldsResearch in context by Jessica Samuelsson, Anna Marseglia, Ola Wallengren, Olof Lindberg, Caroline Dartora, Nira Cedres, Sara Shams, Silke Kern, Anna Zettergren, Eric Westman, Ingmar Skoog

“…Summary: Background: A better understanding of body-brain links may provide insights on targets for preventing cognitive decline. The aim was to explore associations of body composition with neuroimaging biomarkers and cognitive function among dementia-free 70-year-olds. …”
Get full text

Sex-dependent efficacy of sphingosine-1-phosphate receptor agonist FTY720 in mitigating Huntington’s disease by Jingyun Wu, Irene Santos-Garcia, Ivan Eiriz, Thomas Brüning, Aleš Kvasnička, David Friedecký, Tuula A. Nyman, Jens Pahnke

“…Huntington's disease (HD) is a debilitating neurodegenerative disorder characterized by severe motor deficits, cognitive decline and psychiatric disturbances. An early and significant morphological hallmark of HD is the activation of astrocytes triggered by mutant huntingtin, leading to the release of inflammatory mediators.Fingolimod (FTY), an FDA-approved sphingosine-1-phosphate (S1P) receptor agonist is used to treat multiple sclerosis (MS), a neuroinflammatory disease, and has shown therapeutic promise in other neurological conditions.Our study aimed to investigate the therapeutic potential of FTY for treating HD by utilizing a well-characterized mouse model of HD (zQ175dn) and wild-type littermates.The study design included a crossover, long-term oral treatment with 1 mg/kg to 2 mg/kg FTY from the age of 15–46 weeks (n = 128). …”
Get full text

Application of the Uniform Data Set version 3 tele-adapted test battery (T-cog) for remote cognitive assessment preoperatively in older adults by Mika M. Rockholt, Mika M. Rockholt, Rachel R. Wu, Rachel R. Wu, Elaine Zhu, Elaine Zhu, Raven Perez, Raven Perez, Hamleini Martinez, Hamleini Martinez, Jessica J. Hui, Ekow B. Commeh, Romario B. Denoon, Gabrielle Bruno, Braden V. Saba, Daniel Waren, Courtney O'Brien, Vinay K. Aggarwal, Joshua C. Rozell, David Furgiuele, William Macaulay, Ran Schwarzkopf, Evan T. Schulze, Ricardo S. Osorio, Lisa V. Doan, Lisa V. Doan, Jing Wang, Jing Wang, Jing Wang

“…More comprehensive test batteries, such as the Uniform Data Set (UDS) Neuropsychological Battery, and its remote testing version, the Uniform Data Set version 3 tele-adapted test battery (UDS v3.0 T-cog), have been developed to assess cognitive decline in normal aging and disease conditions, but have not been applied in the perioperative setting.MethodsWe assessed the feasibility of using this remote UDS v3.0 T-cog battery for preoperative cognitive assessment in 81 older adults 65+ scheduled for lower extremity joint replacement surgery.ResultsOur results indicate that the UDS v3.0 T-cog achieves 99% completion rates and demonstrates high patient satisfaction. …”
Get full text

Blood levels of cytokines highlight the role of inflammation in Alzheimer's disease by Lorenzo Campanelli, Pablo Galeano, Federico A. Prestia, Carolina Cuesta, Maria C. Dalmasso, María Flores-López, Cristian Gona, Nicolás Irureta, Claudia Kairiyama, Julieta Lisso, Antonio Jesús López-Gambero, Ines Mintz, Nancy Medel, Karen S. Campuzano, Carolina Muchnik, Gisela V. Novack, Natividad Olivar, Ivana Quiroga, Nerea Requena-Ocaña, Jose Antonio Reyes-Bueno, Pedro Serrano-Castro, Zulma Sevillano, Patricia Solis, Juan Suárez, Ivana Villella, Nancy Wukitsevits, Eduardo M. Castaño, Fernando Taragano, Silvia Kochen, Daniel G. Politis, Luis I. Brusco, Fernando Rodríguez de Fonseca, Laura Morelli

“…In this observational case-control study, we aimed to determine plasma levels of cytokines as indicators of inflammation involved in cognitive decline. We measured 30 plasma proteins in 49 controls (CTL), 36 individuals with mild cognitive impairment (MCI) and 52 patients diagnosed with probable AD. …”
Get full text

Association between Community Ambulation Walking Patterns and Cognitive Function in Patients with Parkinson’s Disease: Further Insights into Motor-Cognitive Links by Aner Weiss, Talia Herman, Nir Giladi, Jeffrey M. Hausdorff

“…These findings suggest that metrics derived from a 3-day worn body-fixed sensor reflect cognitive function, further supporting the idea that the gait pattern may be altered as cognition declines and that gait provides a window into cognitive function in patients with PD.…”
Get full text

Neuroplastic Effects of Combined Computerized Physical and Cognitive Training in Elderly Individuals at Risk for Dementia: An eLORETA Controlled Study on Resting States by Charis Styliadis, Panagiotis Kartsidis, Evangelos Paraskevopoulos, Andreas A. Ioannides, Panagiotis D. Bamidis

“…Our results indicate that combined physical and cognitive training shows indices of a positive neuroplastic effect in MCI patients and that EEG may serve as a potential index of gains versus cognitive declines and neurodegeneration. This trial is registered with ClinicalTrials.gov Identifier NCT02313935.…”
Get full text